SillaJen, Inc.

KOSDAQ 215600.KQ

SillaJen, Inc. Receivables for the year ending December 31, 2023: USD 111.09 K

SillaJen, Inc. Receivables is USD 111.09 K for the year ending December 31, 2023, a -65.69% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.
  • SillaJen, Inc. Receivables for the year ending December 31, 2022 was USD 323.78 K, a 54.47% change year over year.
  • SillaJen, Inc. Receivables for the year ending December 31, 2021 was USD 209.61 K, a -90.14% change year over year.
  • SillaJen, Inc. Receivables for the year ending December 31, 2020 was USD 2.13 M, a -28.63% change year over year.
  • SillaJen, Inc. Receivables for the year ending December 31, 2019 was USD 2.98 M, a 0.00% change year over year.
Key data
Date Receivables Inventory Goodwill Total Assets
Market news
SV Wall Street
KOSDAQ: 215600.KQ

SillaJen, Inc.

CEO Mr. Jaekyung Kim
IPO Date Dec. 6, 2016
Location South Korea
Headquarters O2 Tower
Employees 37
Sector Healthcare
Industries
Biotechnology Vaccines
Description

SillaJen, Inc. engages in the development and commercialization of oncolytic immunotherapy products. The company's lead product is Pexa-Vec, which is in Phase II clinical trial for the treatment of advanced liver cancer. It also develops JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. The company was founded in 2006 and is headquartered in Seoul, South Korea.

StockViz Staff

February 4, 2025

Any question? Send us an email